Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Major Shareholder Group Gp Lp Column III Acquires 35,714,284 Shares

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) major shareholder Group Gp Lp Column III bought 35,714,284 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average cost of $0.70 per share, for a total transaction of $24,999,998.80. Following the purchase, the insider now directly owns 49,313,559 shares in the company, valued at $34,519,491.30. This trade represents a 262.62 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Tenaya Therapeutics Stock Down 3.2 %

Shares of NASDAQ:TNYA opened at $0.46 on Monday. Tenaya Therapeutics, Inc. has a 52 week low of $0.39 and a 52 week high of $6.47. The firm has a fifty day simple moving average of $1.14 and a two-hundred day simple moving average of $1.88. The stock has a market capitalization of $36.05 million, a P/E ratio of -0.32 and a beta of 2.83.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TNYA shares. Chardan Capital reiterated a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research note on Monday, February 3rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $17.33.

Institutional Investors Weigh In On Tenaya Therapeutics

Several institutional investors have recently modified their holdings of TNYA. Synovus Financial Corp bought a new position in shares of Tenaya Therapeutics during the 3rd quarter valued at approximately $28,000. Woodline Partners LP purchased a new position in Tenaya Therapeutics during the fourth quarter worth $28,000. Commerce Bank purchased a new stake in shares of Tenaya Therapeutics in the fourth quarter valued at $29,000. Mariner LLC bought a new stake in shares of Tenaya Therapeutics in the 4th quarter worth about $30,000. Finally, Ground Swell Capital LLC purchased a new position in shares of Tenaya Therapeutics during the 4th quarter worth about $32,000. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.